Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Lithium Americas Corp (LAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Lithium Americas Corp — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.97 (market cap $31.07B), while Lithium Americas Corp trades at $2.1 (market cap $800.75M). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 38.8× Lithium Americas Corp's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals.
| GEHC | LAC | |
|---|---|---|
Market Cap | $31.07B | $800.75M |
Volume | 3,443,020 | 6,634,849 |
Sector | Health | Basic Materials |
52-Week High | $88.16 | $9.44 |
52-Week Low | $59.48 | $2.07 |
Enterprise Value | $39.53B | $1.14B |
Dividend Yield | 0.23% | — |
Typical Hold Time | — | 27 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Lithium Americas (LAC) trades at $2.20, down 2.22% with bearish technical signals but positive analyst sentiment. The company shows negative profitability metrics with ROE at -9.56% and net income of -$122.09M for 2025, though it has beaten earnings expectations in recent quarters. Strong financing activity ($1.14B in 2025) supports Thacker Pass development, a key growth catalyst.
LAC presents a high-risk, high-reward opportunity with analyst consensus price target of $4.00 (82% upside). While current fundamentals are weak due to pre-revenue phase, successful execution at Thacker Pass could drive significant revaluation. Key risks include lithium price volatility, project execution challenges, and continued cash burn during development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →
